BGBIO.OL

BerGenBio ASA [BGBIO.OL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BGBIO.OL Stock Summary

In the News

BGBIO.OL Financial details

Company Rating
-
Market Cap
437.72M
Income
-226.32M
Revenue
389K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
23 May 2024
P/E
-3.84
Forward P/E
-
PEG
3.29
P/S
2224.76
P/B
5.4
P/C
-
P/FCF
-3.19
Quick Ratio
6.33
Current Ratio
7.01
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.35
EPS next Y
-
EPS next Q
-
EPS this Y
-2.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-33.77%
Revenue last 5Y
-30.12%
Revenue Q/Q
-
EPS Q/Q
-92.87%
-
-
-
-
SMA20
2.33%
SMA50
-77.92%
SMA100
-83.88%
Inst Own
-
Inst Trans
-
ROA
-120%
ROE
-199%
ROC
-1.39%
Gross Margin
100%
Oper. Margin
-57758%
Profit Margin
-58179%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.075-4.230523
52W High
-
52W Low
-
RSI
37.79
Rel Volume
0.01
Avg Volume
47.7M
Volume
268.47K
Perf Week
-1.17%
Perf Month
11.92%
Perf Quarter
-78.17%
Perf Half Y
-80.26%
-
-
-
-
Beta
1.399
-
-
Volatility
0.04%, 0.09%
Prev Close
-3.98%
Price
1.69
Change
-6.11%

Something similar

Top by Market Cap
META
BRK-B
1YD.DE
TSLA
ABEC.DE
Same Sector
EKSO
VIMTALABS.NS
AMYT.L
CRXM
002620.KS
Same Price Range
DIST.ST
SXTC
ELRE
1854.HK
1749.HK
Similar Market Cap
8476.HK
BUFF
AERI3.SA
ZPRD.DE
2882.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 47.7M
  • Market Capitalization 437.72M
  • Employee 18
  • CEO Mr. Martin Olin
  • Headquarters Bergen,NO
  • IPO Date 2017-04-07
  • Website https://www.bergenbio.com

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.